The bacterial protein azurin and its derived peptide (p28) have been shown to possess anticancer activities. Up to date, several in vitro and in vivo studies have reported their multi-targeted anticancer properties. Moreover, p28, a cell-penetrating peptide, has completed two US phase I trials with promising results.
